JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today announced two significant additions to its global oncology biologic portfolio with the recent launches of LONQUEX® (lipegfilgrastim) and GRANIX™ (tbo-filgrastim) Injection, and an update on the review status of balugrastim by the U.S. Food and Drug Administration (FDA).
Help employers find you! Check out all the jobs and post your resume.
